The present invention relates to an acetylated amphiphilic carbohydrate compound of average molecular weight 1-50 kDa which is based on a glycol chitosan, wherein the levels of acetylation can be modified. The compound can be formulated with hydrophobic compounds such as drugs. The degree of acetylation of the carbohydrate compound is optimised to maximise solubilisation of the drugs. The compound is formulated with drugs and is useful in therapy.

The present invention relates to an acetylated amphiphilic carbohydrate compound of average molecular weight 1-50 kDa which is based on a glycol chitosan, wherein the levels of acetylation can be modified. The compound can be formulated with hydrophobic compounds such as drugs. The degree of acetylation of the carbohydrate compound is optimised to maximise solubilisation of the drugs. The compound is formulated with drugs and is useful in therapy.

The present invention relates to an acetylated amphiphilic carbohydrate compound of average molecular weight 1-50 kDa which is based on a glycol chitosan, wherein the levels of acetylation can be modified. The compound can be formulated with hydrophobic compounds such as drugs. The degree of acetylation of the carbohydrate compound is optimised to maximise solubilisation of the drugs. The compound is formulated with drugs and is useful in therapy.

The present invention relates to a composition comprising cyclosporine A (CsA) for use in the prevention of bronchiolitis obliterans syndrome (BOS) in a double lung transplanted patient, or for the treatment of BOS or for the prevention or delay of the progression of BOS in a double lung transplanted patient being diagnosed with BOS, wherein the composition is administered to said patient by inhalation of said composition in aerosolized form comprising a therapeutically effective dose of cyclo-sporine A.

The present invention relates to a composition comprising cyclosporine A (CsA) for use in the prevention of bronchiolitis obliterans syndrome (BOS) in a double lung transplanted patient, or for the treatment of BOS or for the prevention or delay of the progression of BOS in a double lung transplanted patient being diagnosed with BOS, wherein the composition is administered to said patient by inhalation of said composition in aerosolized form comprising a therapeutically effective dose of cyclo-sporine A.

The present invention relates, inter alia, to a method of preventing or treating skin cancer or skin precancer, the method comprising locally administering to the skin of a subject in need thereof an effective amount of a compound of Formula (I) or a pro-drug thereof, Formula (I) wherein the subject is being administered an immunosuppressant agent that binds to FKBP12. The agent that binds to FKBP12 may be tacrolimus. The invention also relates to methods of preventing or treating a skin condition, disorder or disease associated with administration of an immunosuppressant agent that binds to FKBP12, and to uses of the compound of Formula (I) in treating skin cancer or skin precancer, or a skin condition, disorder or disease associated with administration of an immunosuppressant agent that binds to FKBP12.

##STR00001##

The present invention relates, inter alia, to a method of preventing or treating skin cancer or skin precancer, the method comprising locally administering to the skin of a subject in need thereof an effective amount of a compound of Formula (I) or a pro-drug thereof, Formula (I) wherein the subject is being administered an immunosuppressant agent that binds to FKBP12. The agent that binds to FKBP12 may be tacrolimus. The invention also relates to methods of preventing or treating a skin condition, disorder or disease associated with administration of an immunosuppressant agent that binds to FKBP12, and to uses of the compound of Formula (I) in treating skin cancer or skin precancer, or a skin condition, disorder or disease associated with administration of an immunosuppressant agent that binds to FKBP12.

##STR00001##

Compositions and methods for the treatment of hair growth and the prevention of hair loss.

Compositions and methods for the treatment of hair growth and the prevention of hair loss.

A particle includes at least one or more kinds of substrate and lipid nanoparticles. The lipid nanoparticles are dispersed in the substrate and contain a physiologically active substance. The lipid nanoparticles are one or more kinds selected from liposomes, lipid emulsions, and solid lipid nanoparticles. A corresponding powder inhalant contains the particle. A production method for the particle includes granulating and drying, in which a suspension containing the substrate and the lipid nanoparticles are granulated and dried in a gas medium.